ll-37
LL-37 Cathelicidin Membrane Mechanism and the Dürr Evidence
A sourcing-focused look at LL-37's cathelicidin membrane mechanism, the Dürr evidence behind it, and how listings and COAs document this host-defense peptide.
Medically reviewed by Natalia Sorokin, PhD, research scientist and biochemist — Last reviewed
Natalia Sorokin, PhD holds a doctorate in biochemistry from Moscow State University and postdoctoral training at the Scripps Research Institute, with over 18 years in synthetic peptide chemistry and pharmaceutical-grade peptide production.
Searching for the LL-37 cathelicidin membrane mechanism and the Dürr evidence behind it usually means one thing: trying to understand what “membrane-active” means on a listing page, and whether the mechanism language traces back to anything published rather than to marketing shorthand. LL-37 is the only cathelicidin-family peptide produced in humans, and its defining property in the research literature is how it interacts with lipid membranes. This article does not describe what LL-37 does in a person. It focuses on the membrane mechanism itself, the structural evidence associated with Dürr and colleagues that established the current model, and how that terminology should show up — or fails to show up — on a supplier’s specification page.
What “cathelicidin” and “LL-37” mean on a listing
Cathelicidins are a family of host-defense peptides found across many mammals, named for a shared cathelin-domain precursor structure. LL-37 is the mature, active fragment cleaved from the human precursor protein, and it is the only cathelicidin peptide humans produce — a detail worth checking against any listing, since some pages loosely use “cathelicidin” as if it were interchangeable with the LL-37 sequence itself rather than the broader family name. A complete listing should state the specific 37-residue sequence, note that the name derives from its length and the leading leucine-leucine residues, and distinguish the synthetic peptide from cathelicidin-family peptides found in other species, which are sometimes referenced in older comparative literature.
The membrane mechanism the Dürr evidence describes
LL-37’s defining structural feature is that it forms an amphipathic alpha-helix when it associates with a lipid membrane — one face of the helix is hydrophobic, the other carries a net positive charge. The widely cited structural synthesis associated with Dürr and colleagues compiled spectroscopic and biophysical evidence for how this shape translates into membrane activity: an initial electrostatic attraction between the peptide’s cationic face and negatively charged lipid headgroups, followed by insertion of the hydrophobic face into the bilayer. At low peptide-to-lipid ratios, LL-37 tends to lie along the membrane surface; at higher local concentrations, accumulated peptide can thin and disrupt the bilayer in a detergent-like, carpet-style pattern rather than forming a single stable channel. This is a qualitative description of a concentration-dependent process studied in model membrane systems, not a fixed threshold or a claim about any outcome in a living organism.
Work describing detergent-free approaches to isolating membrane proteins and studying them in a near-native lipid environment is representative of the kind of methodology this structural picture depends on — strategies for keeping membrane proteins in a near-native environment during isolation illustrate why the choice of lipid system changes what a membrane-interaction study can actually measure. Separately, research on biomimetic interfaces built from S-layer proteins and lipid membranes describes the kind of model-membrane platform used to characterize how amphipathic peptides like LL-37 behave at a lipid interface, since bilayer geometry and composition both shape the observed interaction pattern.
How this terminology appears on LL-37 listings
Two distinct kinds of information often sit on the same LL-37 product page, and separating them is the main task for a careful buyer:
- Analytical specification data — sequence, molecular weight, and purity as measured by HPLC or mass spectrometry on the specific lot being sold. This is verifiable against a certificate of analysis.
- Mechanism language — references to amphipathic structure, membrane binding, or the cathelicidin family drawn from the broader research literature. This describes what has been studied about LL-37 generally, not a property confirmed for the specific vial in hand.
Vendors that catalogue a wide range of host-defense and immune-signaling peptides alongside LL-37 sometimes cross-reference related entries so a researcher can compare specification depth across peptide classes on one page — an entry such as the HEEZ Research listing for KPV is the kind of adjacent reference a broad-catalogue source might place near LL-37 for that reason. A narrow, single-compound listing will not have this cross-referencing option, which is a useful signal about catalogue breadth independent of the mechanism description itself.
COA elements specific to a membrane-active peptide
| COA element | What it confirms | Why it matters for LL-37 |
|---|---|---|
| HPLC purity (%) | Fraction of material resolving as the target peak | Standard for any synthetic peptide |
| Mass spectrometry confirmation | Molecular identity matches the 37-residue sequence | Confirms no truncation or deletion in synthesis |
| Sequence verification | Correct residue order, including terminal residues | Amphipathic helix formation depends on residue placement |
| Lot number matching vial | Ties the document to the specific unit shipped | Standard traceability requirement |
| Storage/appearance notes | Handling conditions for the lyophilized peptide | Cationic peptides can be sensitive to aggregation on storage |
A purity figure above a stated threshold on an HPLC trace confirms synthesis quality; it does not confirm that the peptide adopts the helical conformation described in membrane-mechanism literature, since that conformation depends on the lipid or membrane-mimetic environment the peptide is placed in, not on the dry peptide alone.
Vial format and storage notes tied to the mechanism
LL-37 is typically supplied as a lyophilized powder, and its cationic, amphipathic character is part of why storage guidance matters more than it might for a simpler linear peptide. A specification sheet that notes recommended storage temperature, protection from repeated freeze-thaw cycles, and a stated reconstituted shelf life is giving a buyer more usable information than one that lists only a vial mass and a purity percentage. None of this constitutes dosing guidance; it is a description of what stability documentation a complete listing should include for a peptide whose activity is tied to a specific structural conformation.
Comparing listing completeness across sources
Buyers researching the LL-37 cathelicidin membrane mechanism and sourcing questions together will find real variation in how much documentation different suppliers surface. Some publish a lot-matched COA image with sequence and mass-spec data attached. Others describe the membrane mechanism in prose, citing “Dürr” or similar structural work by name, without linking to a primary source at all. A reasonable practice is to treat a mechanism claim without any citation as unverified narrative rather than as documented evidence, and to check separately whether the analytical specification data — purity, sequence, mass spec — is present and lot-matched, since a page can describe the biology accurately while still omitting the batch-specific verification a researcher actually needs. For general background on what a complete certificate of analysis should include, see what a certificate of analysis for research peptides documents.
Summary
LL-37’s membrane mechanism — an amphipathic helix that inserts into lipid bilayers in a concentration-dependent, carpet-like pattern — is a well-characterized structural finding, with the Dürr-associated synthesis widely cited as the reference point for how the evidence fits together. None of that description says anything about outcomes in a person. What it does is give a buyer a way to check a listing: whether the mechanism language is cited, whether the analytical specification data is separately verified and lot-matched, and whether storage guidance reflects the peptide’s structural sensitivities. A listing that keeps these categories distinct is giving a more complete picture than one that blends mechanism narrative and specification data into a single claim.